Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 50

Sort by

Sort Order Select

Journal Articles

Genomic Characterization of Acute Myeloid Leukemia with Aberrations of Chromosome 7: A Multinational Cohort of 523 Patients

Blood (2023) 142 (Supplement 1): 63.

https://doi.org/10.1182/blood-2023-185627

Published: 2023

Journal Articles

Genomic landscape and clonal evolution of acute myeloid leukemia with t(8;21): an international study on 331 patients

Blood (2019) 133 (10): 1140–1151.

https://doi.org/10.1182/blood-2018-05-852822

Published: 2019

Includes: Supplemental data

Journal Articles

No evidence that CD33 splicing SNP impacts the response to GO in younger adults with AML treated on UK MRC/NCRI trials

Rosemary E. Gale, Teodora Popa, Melissa Wright, Naeem Khan, Sylvie D. Freeman, Alan K. Burnett, Nigel H. Russell, Robert K. Hills, David C. Linch

Blood (2018) 131 (4): 468–471.

https://doi.org/10.1182/blood-2017-08-802157

Published: 2018

Includes: Supplemental data

Journal Articles

Activation of the LMO2 oncogene through a somatically acquired neomorphic promoter in T-cell acute lymphoblastic leukemia

Blood (2017) 129 (24): 3221–3226.

https://doi.org/10.1182/blood-2016-09-742148

Published: 2017

Includes: Supplemental data

Journal Articles

A randomized assessment of adding the kinase inhibitor lestaurtinib to first-line chemotherapy for FLT3-mutated AML

Steven Knapper, Nigel Russell, Amanda Gilkes, Robert K. Hills, Rosemary E. Gale, James D. Cavenagh, Gail Jones, Lars Kjeldsen, Michael R. Grunwald, Ian Thomas, Heiko Konig, Mark J. Levis, Alan K. Burnett

Blood (2017) 129 (9): 1143–1154.

https://doi.org/10.1182/blood-2016-07-730648

Published: 2017

Includes: Supplemental data

Journal Articles

Activation of the LMO2 Oncogene in T-ALL through a Somatically Acquired Neomorphic Promoter

Sunniyat Rahman, PhD DIC, MBiochem, Michael Magnussen, MSc, BSc, Theresa E. León, PhD MSc, BSc, Nadine Farah, FRCPath, MBBChir, MA, MRCP, Brian J. Abraham, PhD BSc, Zhaodong Li, PhD, Krisztina Z. Alapi, PhD MSc, BSc, Rachel J. Mitchell, MSc, Bsc, Tom Naughton, MSc, BSc, Adele K. Fielding, MB BS, PhD FRCP, FRCPath, Arnold Pizzey, Sophia Bustraan, BSc, Christopher Allen, BSc, Rosemary E. Gale, PhD BSc, David C. Linch, MD MRCP, MB BCh, BA, Richard A. Young, PhD BS, A. Thomas Look, MD, Marc R Mansour, MBChB, MRCP, PhD FRCPath

Blood (2016) 128 (22): 733.

https://doi.org/10.1182/blood.V128.22.733.733

Published: 2016

Journal Articles

Prevalence of TP53 Mutations in Del(17p) Myeloma: Spectrum of Mutations and Effect on Survival

Melody Chin, BSc, MSc, Jonathan Sive, MBBS, Christopher Allen, BSc, Claire Roddie, MD PhD, Selina J Chavda, MBBS BSc MRCP, Dean Smith, MBBS, Rakesh Popat, Ali Rismani, MBBS, Shirley D'Sa, Neil Rabin, Rosemary E. Gale, PhD BSc, Kwee L Yong

Blood (2016) 128 (22): 4455.

https://doi.org/10.1182/blood.V128.22.4455.4455

Published: 2016

Journal Articles

Downregulation of the Wnt inhibitor CXXC5 predicts a better prognosis in acute myeloid leukemia

Blood (2015) 125 (19): 2985–2994.

https://doi.org/10.1182/blood-2014-12-613703

Published: 2015

Includes: Supplemental data

Journal Articles

The Use of DNA Methylation Profiling to Assess the Significance of Different Types of Mutations in CEBPA -Mutated AML

Dima El-Sharkawi, MBBS, Claire L Green, PhD, Duncan Sproul, PhD, Sarah Jenkinson, MSc, Andrew Feber, PhD, David C Linch, FMedSci, Rosemary E Gale

Blood (2014) 124 (21): 2328.

https://doi.org/10.1182/blood.V124.21.2328.2328

Published: 2014

Journal Articles

The Impact of Different DNMT3A Mutations on Outcome in Younger Adults with Acute Myeloid Leukemia

Rosemary E Gale, Katarina Lamb, BSc, Christopher Allen, BSc, Dima El-Sharkawi, MBBS, Cassandra Stowe, MSc, Sarah Jenkinson, MSc, Steven Tinsley, PhD, Glenda Dickson, PhD, Alan K. Burnett, MD, Robert K. Hills, MA, MSc, DPhil, David C Linch, FMedSci

Blood (2014) 124 (21): 67.

https://doi.org/10.1182/blood.V124.21.67.67

Published: 2014

Journal Articles

Molecular Detection of Minimal Residual Disease Provides the Most Powerful Independent Prognostic Factor Irrespective of Clonal Architecture in Nucleophosmin (NPM1) Mutant Acute Myeloid Leukemia

Blood (2014) 124 (21): 70.

https://doi.org/10.1182/blood.V124.21.70.70

Published: 2014

Journal Articles

Functional and Genetic Heterogeneity of Distinct Leukemic Stem Cell Populations in CD34- Human Acute Myeloid Leukemia

Blood (2014) 124 (21): 15.

https://doi.org/10.1182/blood.V124.21.15.15

Published: 2014

Journal Articles

No Evidence That PTEN Abnormalities Impact on Outcome in Pediatric Patients with T-Cell Acute Lymphoblastic Leukemia (T-ALL) Treated on the MRC UKALL2003 Trial

Sarah Jenkinson, MSc, Amy A Kirkwood, Nicholas Goulden, MD PhD, Ajay J. Vora, Chris Mitchell, Rachel Wade, Jeremy Hancock, Anthony V. Moorman, PhD, David C Linch, FMedSci, Rosemary E Gale

Blood (2014) 124 (21): 1077.

https://doi.org/10.1182/blood.V124.21.1077.1077

Published: 2014

Journal Articles

The Sub-Clonal Complexity of STIL-TAL1 T-ALL

Caroline L Furness, MD, Marcela B Mansur, PhD, Victoria J Weston, PhD, Sarah Jenkinson, MSc, Frederik W van Delft, MDPhD, Lyndal Kearney, PhD, Ian Titley, PhD, Anthony M Ford, PhD, Rosemary E Gale, Pamela R Kearns, MBChB, PhD FRCPCH, Adolfo A. Ferrando, MD PhD, Christine J. Harrison, Nicola E Potter, PhD, Mel Greaves, FRS

Blood (2014) 124 (21): 3788.

https://doi.org/10.1182/blood.V124.21.3788.3788

Published: 2014

Journal Articles

X chromosome inactivation analysis reveals a difference in the biology of ET patients with JAK2 and CALR mutations

Christopher Allen, Jonathan R. Lambert, David C. Linch, Rosemary E. Gale

Blood (2014) 124 (13): 2091–2093.

https://doi.org/10.1182/blood-2014-06-580183

Published: 2014

Journal Articles

Impact of FLT3 ITD mutant allele level on relapse risk in intermediate-risk acute myeloid leukemia

David C. Linch, Robert K. Hills, Alan K. Burnett, Asim Khwaja, Rosemary E. Gale

Blood (2014) 124 (2): 273–276.

https://doi.org/10.1182/blood-2014-02-554667

Published: 2014

Includes: Supplemental data

Journal Articles

Familial AML With Germline CEBPA Mutations: Extended Clinical Outcomes and Analysis Of Secondary Mutations Using Whole Exome Sequencing

Kiran Tawana, MD, Aline Renneville, Jun Wang, PhD, Panayiotis Georgiades, Xavier Thomas, MD, Valerie Mialou, MD, Aleksander Savic, MD, Frederik W Van Delft, MD PhD, Jennifer G. Treleaven, MD, Sameena Iqbal, Norio Asou, MD, PhD, Naokuni Uike, MD, Konstanze Döhner, MD, Lars Bullinger, MD, PhD, Matthias Stelljes, MD, Csaba Bödör, PhD, James D. Cavenagh, MD, Doris Steinemann, PhD, Tim Ripperger, MD, Brigitte Schlegelberger, MD, PhD, Peter Vandenberghe, MD, PhD, Anne Uyttebroeck, MD, Josep F. Nomdedeu, MD, Henrik Hjorth-Hansen, MD, PhD, Rosemary E Gale, PhD, Cynthia L. Toze, MD, FRCP(C), Michael J. Barnett, BMBS, FRCPC, FRCP, FRCPath, Marianna Zombori, MD, Krisztian Kallay, MD, Jiri Pavlu, MD, Pim Mutsaers, MD, Fred H Menko, MD, Angela Thomas, PhD, FRCPath, FRCP, MB, BS, Christine Wright, MD, Jessica Okosun, MD, Chey Loveday, PhD, Pierre Fenaux, MD, PhD, Hamish Scott, PhD, Claude Preudhomme, Claude Chelala, PhD, Alison Male, MD, Carolyn J. Owen, MD, FRCPC, Matthew Smith, MD, PhD, Jude Fitzgibbon, PhD

Blood (2013) 122 (21): 740.

https://doi.org/10.1182/blood.V122.21.740.740

Published: 2013

Journal Articles

Downregulation Of The Wnt Inhibitor CXXC5 Predicts a Better Prognosis In Acute Myeloid Leukemia

Blood (2013) 122 (21): 52.

https://doi.org/10.1182/blood.V122.21.52.52

Published: 2013

Journal Articles

Impact of isolated germline JAK2V617I mutation on human hematopoiesis

Adam J. Mead, Onima Chowdhury, Christian Pecquet, Alexandra Dusa, Petter Woll, Deborah Atkinson, Adam Burns, Joannah Score, Michelle Rugless, Ruth Clifford, Simon Moule, Nicola Bienz, Paresh Vyas, Nick Cross, Rosemary E. Gale, Shirley Henderson, Stefan N. Constantinescu, Anna Schuh, Sten Eirik W. Jacobsen

Blood (2013) 121 (20): 4156–4165.

https://doi.org/10.1182/blood-2012-05-430926

Published: 2013

Includes: Supplemental data

Journal Articles

PI3K/mTOR Inhibition Upregulates NOTCH-MYC Signalling Leading to an Impaired Cytotoxic Response

Clare Shepherd, PhD, Lalita Banerjee, FRCPath, Ching Wai Cheung, FRCPath, Marc R Mansour, MRCP, Sarah Jenkinson, MSc, Rosemary E Gale, PhD, Asim Khwaja, FRCPath

Blood (2012) 120 (21): 1358.

https://doi.org/10.1182/blood.V120.21.1358.1358

Published: 2012

NARROW

Genomic Characterization of Acute Myeloid Leukemia with Aberrations of Chromosome 7: A Multinational Cohort of 523 Patients

Genomic landscape and clonal evolution of acute myeloid leukemia with t(8;21): an international study on 331 patients

No evidence that CD33 splicing SNP impacts the response to GO in younger adults with AML treated on UK MRC/NCRI trials

Activation of the LMO2 oncogene through a somatically acquired neomorphic promoter in T-cell acute lymphoblastic leukemia

A randomized assessment of adding the kinase inhibitor lestaurtinib to first-line chemotherapy for FLT3-mutated AML

Activation of the LMO2 Oncogene in T-ALL through a Somatically Acquired Neomorphic Promoter

Prevalence of TP53 Mutations in Del(17p) Myeloma: Spectrum of Mutations and Effect on Survival

Downregulation of the Wnt inhibitor CXXC5 predicts a better prognosis in acute myeloid leukemia

The Use of DNA Methylation Profiling to Assess the Significance of Different Types of Mutations in CEBPA -Mutated AML

The Impact of Different DNMT3A Mutations on Outcome in Younger Adults with Acute Myeloid Leukemia

Molecular Detection of Minimal Residual Disease Provides the Most Powerful Independent Prognostic Factor Irrespective of Clonal Architecture in Nucleophosmin (NPM1) Mutant Acute Myeloid Leukemia

Functional and Genetic Heterogeneity of Distinct Leukemic Stem Cell Populations in CD34- Human Acute Myeloid Leukemia

No Evidence That PTEN Abnormalities Impact on Outcome in Pediatric Patients with T-Cell Acute Lymphoblastic Leukemia (T-ALL) Treated on the MRC UKALL2003 Trial

The Sub-Clonal Complexity of STIL-TAL1 T-ALL

X chromosome inactivation analysis reveals a difference in the biology of ET patients with JAK2 and CALR mutations

Impact of FLT3 ITD mutant allele level on relapse risk in intermediate-risk acute myeloid leukemia

Familial AML With Germline CEBPA Mutations: Extended Clinical Outcomes and Analysis Of Secondary Mutations Using Whole Exome Sequencing

Downregulation Of The Wnt Inhibitor CXXC5 Predicts a Better Prognosis In Acute Myeloid Leukemia

Impact of isolated germline JAK2V617I mutation on human hematopoiesis

PI3K/mTOR Inhibition Upregulates NOTCH-MYC Signalling Leading to an Impaired Cytotoxic Response

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only